{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T04:54:53Z","timestamp":1783227293064,"version":"3.54.6"},"reference-count":114,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Agence Nationale de la Recherche","award":["10-IAHU-03"],"award-info":[{"award-number":["10-IAHU-03"]}]},{"name":"Aix-Marseille University","award":["10-IAHU-03"],"award-info":[{"award-number":["10-IAHU-03"]}]},{"name":"IRD","award":["10-IAHU-03"],"award-info":[{"award-number":["10-IAHU-03"]}]},{"name":"Centre National de la Recherche Scientifique","award":["10-IAHU-03"],"award-info":[{"award-number":["10-IAHU-03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The benefits of SARS-CoV-2 spike mRNA vaccines are well known, including a significant decline in COVID-19 morbidity and a decrease in the mortality rate of SARS-CoV-2 infected persons. However, pharmacovigilance studies have revealed the existence of rare cases of cardiovascular complications after mass vaccination using such formulations. Cases of high blood pressure have also been reported but were rarely documented under perfectly controlled medical supervision. The press release of these warning signals triggered a huge debate over COVID-19 vaccines\u2019 safety. Thereby, our attention was quickly focused on issues involving the risk of myocarditis, acute coronary syndrome, hypertension and thrombosis. Rare cases of undesirable post-vaccine pathophysiological phenomena should question us, especially when they occur in young subjects. They are more likely to occur with inappropriate use of mRNA vaccine (e.g., at the time when the immune response is already very active during a low-noise infection in the process of healing), leading to angiotensin II (Ang II) induced inflammation triggering tissue damage. Such harmful effects observed after the COVID-19 vaccine evoke a possible molecular mimicry of the viral spike transiently dysregulating angiotensin converting enzyme 2 (ACE2) function. Although the benefit\/risk ratio of SARS-CoV-2 spike mRNA vaccine is very favorable, it seems reasonable to suggest medical surveillance to patients with a history of cardiovascular diseases who receive the COVID-19 vaccine.<\/jats:p>","DOI":"10.3390\/v15051045","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T04:27:02Z","timestamp":1682396822000},"page":"1045","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Molecular Mimicry of the Viral Spike in the SARS-CoV-2 Vaccine Possibly Triggers Transient Dysregulation of ACE2, Leading to Vascular and Coagulation Dysfunction Similar to SARS-CoV-2 Infection"],"prefix":"10.3390","volume":"15","author":[{"given":"Christian A.","family":"Devaux","sequence":"first","affiliation":[{"name":"Microbes Evolution Phylogeny and Infection (MEPHI) Laboratory, Aix-Marseille University, Institut de Recherche Pour le D\u00e9veloppement (IRD), Assistance Publique H\u00f4pitaux de Marseille (APHM), Institut Hospitalo-Universitaire (IHU)\u2013M\u00e9diterran\u00e9e Infection, 13005 Marseille, France"},{"name":"Centre National de la Recherche Scientifique (CNRS-SNC5039), 13000 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Camoin-Jau","sequence":"additional","affiliation":[{"name":"Microbes Evolution Phylogeny and Infection (MEPHI) Laboratory, Aix-Marseille University, Institut de Recherche Pour le D\u00e9veloppement (IRD), Assistance Publique H\u00f4pitaux de Marseille (APHM), Institut Hospitalo-Universitaire (IHU)\u2013M\u00e9diterran\u00e9e Infection, 13005 Marseille, France"},{"name":"Laboratoire d\u2019H\u00e9matologie, H\u00f4pital de La Timone, APHM, Boulevard Jean-Moulin, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S1359-6446(05)03600-7","article-title":"The rational design of vaccines","volume":"10","author":"Bramwell","year":"2005","journal-title":"Drug Discov. Today"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Schijns, V., Majhen, D., van der Ley, P., Thakur, A., Summerfield, A., Berisio, R., Nativi, C., Fernandez-Tejada, A., Alvarez-Dominguez, C., and Gizurarson, S. (2021). Rational vaccine design in times of emerging diseases: The critical choices of immunological correlates of protection, vaccine antigen and immunomodulation. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13040501"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 vaccines: Where we stand and challenges ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell. Death Differ."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"108086","DOI":"10.1016\/j.intimp.2021.108086","article-title":"Vaccine design and delivery approaches for COVID-19","volume":"100","author":"Shahzamani","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107679","DOI":"10.1016\/j.intimp.2021.107679","article-title":"Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms","volume":"97","author":"Bayat","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"110235","DOI":"10.1016\/j.celrep.2021.110235","article-title":"Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19","volume":"38","author":"Alcami","year":"2022","journal-title":"Cell Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1016\/j.vaccine.2021.10.079","article-title":"Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework","volume":"39","author":"Lau","year":"2021","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1473-3099(21)00211-5","article-title":"Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: A Danish population-based cohort study","volume":"21","author":"Lund","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"n1005","DOI":"10.1136\/bmj.n1005","article-title":"COVID-19: Risk of cerebral blood clots from disease is 10 times that from vaccination, study finds","volume":"373","author":"Torjesen","year":"2021","journal-title":"Br. Med. J."},{"key":"ref_15","first-page":"n1931","article-title":"Risk of thrombocytopenia and thromboembolism after COVID-19 vaccination and SARS-CoV-2 positive testing: Self-controlled case series study","volume":"374","author":"Patone","year":"2021","journal-title":"Br. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.micinf.2020.03.003","article-title":"Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2","volume":"22","author":"Qiu","year":"2020","journal-title":"Microbes Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jmii.2020.04.015","article-title":"ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome","volume":"53","author":"Devaux","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1042200","DOI":"10.3389\/fmicb.2022.1042200","article-title":"An update on angiotensin-converting enzyme 2 structure\/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection","volume":"13","author":"Devaux","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan","volume":"191","author":"Lodigiani","year":"2020","journal-title":"Italy Thromb. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.amjcard.2021.07.009","article-title":"COVID-19 vaccine and myocarditis","volume":"157","author":"Salah","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40119-021-00248-0","article-title":"Cardiovascular complications of SARS-CoV-2 vaccines: An overview","volume":"11","author":"Shiravi","year":"2022","journal-title":"Cardiol. Ther."},{"key":"ref_23","unstructured":"Craig, C., Neil, M., Fenton, N., McLachlan, S., Smalley, J., Guetzkow, J., Engler, J., Russell, D., and Rose, J. (2022). Official Mortality Data for England Reveal Systematic Undercounting of Deaths Occurring within First Two Weeks of COVID-19 Vaccination, Research Gate Net. Preprint available online (not peer reviewed)."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.12691\/ajmcr-8-12-19","article-title":"Myocarditis associated with COVID-19","volume":"8","author":"Oleszak","year":"2020","journal-title":"Am. J. Med. Case Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/jxym-20-105","article-title":"Effects of COVID-19 on the cardiovascular system and implications for management","volume":"6","author":"Wu","year":"2021","journal-title":"J. Xiangya Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA Vaccine against COVID-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e068665","DOI":"10.1136\/bmj-2021-068665","article-title":"SARS-CoV-2 vaccination and myocarditis or myopericarditis: Population based cohort study","volume":"375","author":"Husby","year":"2021","journal-title":"Br. Med. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M21-3700","article-title":"Carditis After COVID-19 Vaccination with a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case\u2013Control Study","volume":"175","author":"Lai","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_30","first-page":"6978","article-title":"Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave","volume":"12","author":"Sun","year":"2022","journal-title":"Nat. Sci. Rep."},{"key":"ref_31","first-page":"e000373","article-title":"Clinical outcomes of myocarditis after SARS-CoV-2 mRNAvaccination in four Nordic countries: Population based cohort study","volume":"2","author":"Husby","year":"2023","journal-title":"Br. Med. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"n1372","DOI":"10.1136\/bmj.n1372","article-title":"COVID-19: Pfizer-BioNTech vaccine is \u201clikely\u201d responsible for deaths of some elderly patients, Norwegian review finds","volume":"373","author":"Torjsesen","year":"2021","journal-title":"Br. Med. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100042","DOI":"10.1016\/j.ahjo.2021.100042","article-title":"Myocarditis following mRNA vaccination against SARS-CoV-2, a case series","volume":"8","author":"King","year":"2021","journal-title":"Am. Heart. J. Plus Cardiol. Res. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.cjco.2021.07.008","article-title":"Acute myocarditis following mRNA-1273 SARS-CoV-2 vaccination","volume":"3","author":"Williams","year":"2021","journal-title":"CJC Open"},{"key":"ref_35","first-page":"A10712","article-title":"mRNA COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by PULS Cardiac Test: A Warning","volume":"144","author":"Gundry","year":"2021","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3201\/eid2707.210594","article-title":"Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination","volume":"27","author":"Salzman","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., and Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A risk factor of Multisystem Inflammatory Syndrome?. Vaccines, 9.","DOI":"10.3390\/vaccines9111353"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/HYPERTENSIONAHA.121.17316","article-title":"Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination","volume":"77","author":"Meylan","year":"2021","journal-title":"Hypertension"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejim.2021.06.013","article-title":"Blood pressure increase after Pfizer\/BioNTech SARS-CoV-2 vaccine","volume":"90","author":"Zappa","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100159","DOI":"10.1016\/j.metop.2021.100159","article-title":"Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2","volume":"13","author":"Tsilingiris","year":"2022","journal-title":"Metab. Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00228-021-03197-8","article-title":"Hypertension and COVID-19 vaccines: Are there any differences between the different vaccines? A safety signal","volume":"77","author":"Bouhanick","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_43","first-page":"001","article-title":"Suspected cardiovascular side effects of two COVID-19 vaccines","volume":"10","author":"Lehmann","year":"2021","journal-title":"J. Biol. Today World"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.2147\/IJGM.S324349","article-title":"Cardiovascular adverse events reported from COVID-19 vaccines: A study based on WHO Database","volume":"14","author":"Kaur","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/jcph.2037","article-title":"Hypertensive crisis following COVID-19 vaccination","volume":"62","author":"Khani","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_46","unstructured":"Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. (2002). Molecular Biology of the Cell, Garland Science. [4th ed.]. Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK26829\/."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cell.2016.02.058","article-title":"SnapShot: Timescales in cell biology","volume":"164","author":"Shamir","year":"2016","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2021.04.019","article-title":"SARS-CoV-2 vaccines: Lights and shadows","volume":"88","author":"Angeli","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1016\/j.vaccine.2021.09.060","article-title":"Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021","volume":"39","author":"Tran","year":"2021","journal-title":"Vaccine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41371-021-00634-0","article-title":"Blood pressure measurements after mRNA-SARS-CoV-2 tozinameran vaccination: A retrospective analysis in a university hospital in France","volume":"36","author":"Bouhanick","year":"2022","journal-title":"J. Hum. Hypertens."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejim.2022.08.027","article-title":"COVID-19 vaccines effect on blood pressure","volume":"105","author":"Simonini","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Syrigos, N., Kollias, A., Grapsa, D., Fyta, E., Kyriakoulis, K.G., Vathotis, J., Kotteas, E., and Syrigou, E. (2022). Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event. Vaccines, 10.","DOI":"10.3390\/vaccines10050745"},{"key":"ref_53","first-page":"768","article-title":"Changes in blood pressure after Messenger RNA COVID-19 vaccination","volume":"77","author":"Ong","year":"2022","journal-title":"Med. J. Malays."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Angeli, F., Reboldi, G., Trapasso, M., Santilli, G., Zappa, M., and Verdecchia, P. (2022). Blood pressure increase following COVID-19 vaccination: A systematic overview and meta- analysis. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9050150"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2100956","DOI":"10.1183\/13993003.00956-2021","article-title":"Vaccination against COVID-19: Insight from arterial and venous thrombosis occurrence using data from VigiBase","volume":"58","author":"Smadja","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S1473-3099(21)00420-5","article-title":"Heterologous prime\u2013boost vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"21","author":"Tenbusch","year":"2021","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e74974","DOI":"10.7554\/eLife.74974","article-title":"Vaccine-induced COVID-19 mimicry syndrome","volume":"11","author":"Korwarz","year":"2022","journal-title":"eLife"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1016\/j.vaccine.2021.04.054","article-title":"Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"39","author":"Welsh","year":"2021","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"729251","DOI":"10.3389\/fimmu.2021.729251","article-title":"COVID-19 vaccine-related thrombosis: A systematic review and exploratory analysis","volume":"12","author":"Bilotta","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"Heparin-Induced Thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Islam, A., Sheraz Bashir, M., Joyce, K., Rashid, H., Laher, I., and Elshazly, S. (2021). An Update on COVID-19 Vaccine induced thrombotic thrombocytopenia syndrome and some management recommendations. Molecules, 26.","DOI":"10.3390\/molecules26165004"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(21)01608-1","article-title":"Cerebral venous thrombosis after vaccination against COVID-19 in the UK: A multicentre cohort study","volume":"398","author":"Perry","year":"2021","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1055\/a-1499-0119","article-title":"SARS-CoV-2 vaccine and thrombosis: An expert consensus on vaccine-induced immune thrombotic thrombocytopenia","volume":"121","author":"Elalamy","year":"2021","journal-title":"Thromb. Haemost."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e2327","DOI":"10.1002\/rmv.2327","article-title":"SARS-CoV-2-related and COVID-19 vaccine-induced thromboembolic events: A comparative review","volume":"32","author":"Afshar","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-med-043021-015237","article-title":"SARS-CoV-2 vaccination-induced thrombotic thrombocytopenia: A rare but serious immunological complication","volume":"74","author":"Abrams","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/ejh.13665","article-title":"COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome","volume":"107","author":"Franchini","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.seminhematol.2022.03.002","article-title":"Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)","volume":"59","author":"Gabarin","year":"2022","journal-title":"Semin. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S2665-9913(20)30121-1","article-title":"Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia","volume":"2","author":"McGonagle","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"n1435","DOI":"10.1136\/bmj.n1435","article-title":"Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: Multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"Br. Med. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/jmv.27424","article-title":"Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database","volume":"94","author":"Kim","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1016\/j.cell.2021.06.005","article-title":"SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2","volume":"184","author":"Amanat","year":"2021","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2666-5247(21)00275-5","article-title":"T-Cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: A multicentre prospective cohort study","volume":"3","author":"Angyal","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Cantoni, D., Siracusano, G., Mayora-Neto, M., Pastori, C., Fantoni, T., and Lytras, S. (2023). Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms. Vaccines, 11.","DOI":"10.3390\/vaccines11010058"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41591-022-02138-x","article-title":"Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave","volume":"29","author":"Tan","year":"2023","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41586-022-04778-y","article-title":"Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost","volume":"607","author":"Muecksch","year":"2022","journal-title":"Nature"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals after mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Wolf, C., K\u00f6ppert, S., Becza, N., Kuerten, S., Kirchenbaum, G.A., and Lehmann, P.V. (2022). Antibody levels poorly reflect on the frequency of memory B cells generated following SARS-CoV-2, Seasonal Influenza, or EBV infection. Cells, 11.","DOI":"10.21203\/rs.3.rs-1792582\/v1"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"ref_82","first-page":"74","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41467-021-27674-x","article-title":"Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts","volume":"13","author":"Kundu","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s42003-022-03207-0","article-title":"Antibody-dependent enhancement (ADE) of SARSCoV-2 pseudoviral infection requires Fc\u03b3RIIB and virus-antibody complex with bivalent interaction","volume":"5","author":"Wang","year":"2022","journal-title":"Nat. Commun. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Gu\u00e9rin, P., Yahi, N., Azzaz, F., Chahinian, H., Sabatier, J.M., and Fantini, J. (2022). Structural dynamics of the SARS-CoV-2 Spike protein: A 2-year retrospective analysis of SARS-CoV-2 variants (from Alpha to Omicron) reveals an early divergence between conserved and variable epitopes. Molecules, 27.","DOI":"10.3390\/molecules27123851"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"7637","DOI":"10.1128\/JVI.75.16.7637-7650.2001","article-title":"Binding of human immunodeficiency virus type 1 gp120 to CXCR4 induces mitochondrial transmembrane depolarization and cytochrome c-mediated apoptosis independently of Fas signaling","volume":"75","author":"Roggero","year":"2001","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1742-4690-1-12","article-title":"Apoptosis of uninfected cells induced by HIV envelope glycoproteins","volume":"1","author":"Ahr","year":"2004","journal-title":"Retrovirology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/archinte.163.10.1155","article-title":"Renin-angiotensin system and atherothrombotic disease: From genes to treatment","volume":"163","author":"Jacoby","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40292-022-00506-9","article-title":"Hypertension and COVID-19: Current evidence and perspectives","volume":"29","author":"Gallo","year":"2022","journal-title":"High Blood Press. Cardiovasc. Prevent."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0167-0115(00)00178-6","article-title":"The multiple actions of angiotensin II in atherosclerosis","volume":"93","author":"Kagiyama","year":"2000","journal-title":"Regul. Pept."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"15926","DOI":"10.1074\/jbc.M909616199","article-title":"Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc","volume":"275","author":"Heeneman","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/micc.12120","article-title":"Roles of coagulation and fibrinolysis in angiotensin II enhanced microvascular thrombosis","volume":"21","author":"Senchenkova","year":"2014","journal-title":"Microcirculation"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II signal transduction: An update on mechanisms of physiology and pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.mce.2008.11.003","article-title":"NADPH oxidases and angiotensin II receptor signaling","volume":"302","author":"Garrido","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"960308","DOI":"10.3389\/fphys.2022.960308","article-title":"The impact of COVID-19 on populations living at high altitude: Role of hypoxia inducible factors (HIFs) signaling pathway in SARS-CoV-2 infection and replication","volume":"13","author":"Devaux","year":"2022","journal-title":"Front. Physiol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Devaux, C.A., and Lagier, J.C. (2023). Unraveling the Underlying Molecular Mechanism of \u2018Silent Hypoxia\u2019 in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062445"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1161\/01.CIR.0000148824.93600.F3","article-title":"Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines","volume":"110","author":"Nabah","year":"2004","journal-title":"Circulation"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1161\/01.RES.84.6.695","article-title":"Angiotensin II induces Interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kB transcription factors","volume":"84","author":"Han","year":"1999","journal-title":"Circ. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00041552-200105000-00005","article-title":"Proinflammatory actions of angiotensins","volume":"10","author":"Lorenzo","year":"2001","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"625732","DOI":"10.3389\/fimmu.2021.625732","article-title":"Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients","volume":"12","author":"Osman","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1016\/S0021-9258(17)34557-X","article-title":"Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney","volume":"253","author":"Odya","year":"1978","journal-title":"J. Biol. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/HYPERTENSIONAHA.119.14071","article-title":"Ang II (Angiotensin II) conversion to angiotensin-(1- 7) in the circulation Is POP (Prolyloligopeptidase)-dependent and ACE2 (Angiotensin-converting enzyme 2)-independent","volume":"75","author":"Serfozo","year":"2020","journal-title":"Hypertension"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejim.2022.06.015","article-title":"COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the \u201cSpike effect\u201d","volume":"103","author":"Angeli","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Solopov, P.A. (2023). COVID-19 vaccination and alcohol consumption: Justification of risks. Pathogens, 12.","DOI":"10.3390\/pathogens12020163"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/ejh.13917","article-title":"Immune thrombocytopenic purpura secondary to COVID-19 vaccination: A systematic review","volume":"110","author":"Bidari","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1182\/blood.2021015149","article-title":"Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination","volume":"139","author":"Picod","year":"2022","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood.2022015545","article-title":"SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura","volume":"139","author":"Shah","year":"2022","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia (VITT)","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1002\/iid3.807","article-title":"Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia","volume":"11","author":"Yasmin","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood.2022017696","article-title":"Vaccine-induced immune thrombotic thrombocytopenia","volume":"141","author":"Cines","year":"2023","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10140-022-02039-z","article-title":"Incidence of pulmonary embolism in COVID-19 infection in the ED: Ancestral, Delta, Omicron variants and vaccines","volume":"29","author":"Law","year":"2022","journal-title":"Emerg. Radiol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Di Gennaro, C., Galdiero, M., Scherillo, G., Parlamento, S., Poggiano, M.R., Arturo, C., Vasta, A., Giordano, B., Pisano, V., and Lobasso, A. (2022). Editorial COVID-19 and Thrombosis 2023: New waves of SARS-CoV-2 infection, triage organization in emergency department and the association of VOCs\/VOI with pulmonary embolism. Viruses, 14.","DOI":"10.3390\/v14112453"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Kyriakoulis, K.G., Dimakakos, E., Kyriakoulis, I.G., Catalano, M., Spyropoulos, A.C., Schulman, S., Douketis, J., Falanga, A., Maraveyas, A., and Olinic, D.-M. (2022). Practical recommendations for optimal thromboprophylaxis in patients with COVID-19: A consensus statement based on available clinical trials. J. Clin. Med., 11.","DOI":"10.3390\/jcm11205997"},{"key":"ref_114","unstructured":"WGGTMA (Working Group on Guidelines for Thromboprophylaxis and Management of Anticoagulantion in Hospitalized Patients with COVID-19) (2023). Practice guidelines of thromboprophylaxis and management of anticoagulation in hospitalized patients with COVID-19. Zhonghua Yi Xue Za Zhi, 103, 1\u201323. (In Chinese)."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/5\/1045\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:22:54Z","timestamp":1760124174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/5\/1045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":114,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["v15051045"],"URL":"https:\/\/doi.org\/10.3390\/v15051045","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]}}}